Published in Medical Letter on the CDC and FDA, October 24th, 2004
The FDA also has granted priority review status to the BEXXAR BLA. As a result, the companies expect the FDA to complete its review of the BEXXAR sBLA by January 2005.
Corixa has requested accelerated approval for the expanded use of BEXXAR in treatment of patients with relapsed or refractory low-grade, follicular or transformed CD20-positive non-Hodgkin lymphoma (NHL) whose disease has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA